Oramed Pharmaceuticals (ORMP) Stock Analysis & Winston Score

Oramed Pharmaceuticals is a clinical-stage biotech company focused on developing oral versions of drugs that are normally injected. Its main project is an oral insulin capsule for people with diabetes — a disease that affects hundreds of millions of people worldwide. The company is based in Israel and the United States, and it is one of the few companies working specifically on swallowable insulin pills. Oramed does not yet sell any products, so it currently earns no revenue. It funds its research through cash reserves and capital raises, which is typical for clinical-stage biotechs. The company's potential edge is its drug delivery technology, which is designed to protect insulin from being broken down in the stomach. The biggest risk is that its oral insulin candidate must still prove it works well enough in large clinical trials to win regulatory approval — without that, the company has no path to generating real revenue.